- AstraZeneca (NASDAQ:AZN) has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in around 70 countries to Cheplapharm Arzneimittel GmbH.
- Cheplapharm will pay AstraZeneca a total of $400M in non-contingent consideration. Of the $400M, $250M will be payable on completion and the remainder in H1.
- The transaction is expected to be completed in Q4 2020.
- The Company will continue to manufacture, supply and commercialize Atacand and Atacand Plus during a three-year transition period.
- Atacand is a prescription medicine approved for the treatment of heart failure and hypertension and Atacand Plus for hypertension.
https://seekingalpha.com/news/3628929-astrazeneca-to-divest-atacand-rights-in-70-countries-for-400m
Friday, October 30, 2020
AstraZeneca to divest Atacand rights in 70 countries for $400M
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.